Fedratinib - Impact Biomedicines

Alternative Names: SAR-302503; TG-101348

Latest Information Update: 12 Apr 2018

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator TargeGen
Developer Impact Biomedicines; Sanofi
Class Phenyl ethers; Pyrimidines; Pyrrolidines; Small molecules; Sulfonamides
Mechanism of Action Janus kinase-2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase III Myelofibrosis
Phase II Essential thrombocythaemia; Polycythaemia vera
Discontinued Solid tumours

Most Recent Events

12 Apr 2018 Impact Biomedicines has been acquired by Celgene Corporation
07 Jan 2018 Celgene Corporation signs a definitive agreement for acquisition of Impact Biomedicines
07 Jan 2018 Celgene Corporation expects the deal closure for acquisition of Impact Biomedicines in the first quarter of 2018

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.